Document Detail


The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease.
MedLine Citation:
PMID:  15683110     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previously, the inhibition of coronary restenosis with Abciximab (ReoPro)-coated stent in a porcine model was reported. ReoPro inhibits platelet aggregation, the proliferation of vascular smooth muscle cells and the inflammatory reaction.
METHODS: A prospective randomized trial was performed to compare two types of stent for revascularization in the native coronary artery. The primary effective end points were major adverse coronary events (MACE): cardiac death, acute myocardial infarction, target vessel revascularization (TVR) and restenosis at the 6-month clinical and angiographic follow-ups.
RESULTS: One hundred and fifty-five patients were enrolled between August 2001 and June 2003. The mean ages (56.0 +/- 10.0 vs. 56.9 +/- 10.8 years), baseline diameter of stenosis and minimal luminal diameter were no different between the two groups. There was one myocardial infarction and revascularization during the hospital stay in control stent group. During the clinical follow-up there were two myocardial infarctions in control group. Follow-up coronary angiograms were performed in 62.3% (48/77) and 65.4% (51/78) of the coated and control groups, respectively. The diameter of stenosis and late loss were significantly less in the ReoPro-coated stent group compared with the controls (16.4 +/- 5.8% vs. 34.3 +/- 6.1%, p = 0.009; and 0.33 +/- 0.28 mm vs. 0.88 +/- 0.41 mm; p = 0.002). The restenosis and TVR rates of the ReoPro-coated stent were relatively lower compared with the control stent [14.6% (7/48) vs. 29.4% (15/51), p = 0.062; and 9.2% (7/76) vs. 14.7% (11/75); p = 0.327].
CONCLUSION: A ReoPro-coated stent is safe, and may be effective in the prevention of coronary restenosis.
Authors:
Weon Kim; Myung Ho Jeong; Young Joon Hong; Seng Hyun Lee; Woo Seok Park; Ju Han Kim; In Soo Kim; Myung Ja Choi; Young Keun Ahn; Jeong Gwan Cho; Jong Chun Park; Dong Lyun Cho; Hoon Kim; Jung Chaee Kang
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Korean journal of internal medicine     Volume:  19     ISSN:  1226-3303     ISO Abbreviation:  Korean J. Intern. Med.     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2005-02-01     Completed Date:  2005-03-17     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  8712418     Medline TA:  Korean J Intern Med     Country:  Korea (South)    
Other Details:
Languages:  eng     Pagination:  220-9     Citation Subset:  IM    
Affiliation:
The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Chemical Engineering of Chonnam National University, Gwangju, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / pharmacokinetics,  therapeutic use*
Coated Materials, Biocompatible / pharmacokinetics,  therapeutic use*
Coronary Artery Disease / surgery*
Coronary Restenosis / epidemiology,  prevention & control
Female
Humans
Immunoglobulin Fab Fragments / therapeutic use*
Korea / epidemiology
Male
Middle Aged
Platelet Aggregation Inhibitors / pharmacokinetics,  therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Prospective Studies
Stents*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Coated Materials, Biocompatible; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early assessment of myocardial contractility by contrast-enhanced magnetic resonance (ceMRI) imaging...
Next Document:  Effects of cilostazol on platelet activation in coronary stenting patients who already treated with ...